Malignant Melanoma | Treatment Sequencing | EU5 | 2018
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts’ assumptions.
Key Benefits:
- Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
- Drill down into physicians’ treatment sequences and understand who to position against or how to defend share.
- Identify untapped treatment scenarios and key competitors to aid trial design.
- Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.
- Discover untapped populations to expand product share and drive strategic decisions.
Questions Answered:
- Where is my product positioned versus that of competitors in the treatment journey?
- What are physicians’ most frequent treatment sequences; who is benefiting, and how can I defend my asset’s share and position?
- What are the market-relevant treatment scenarios according to oncology experts?
- How can I optimize trial design and ensure a competitive edge for my pipeline asset?
Related Market Assessment Reports
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Malignant Melanoma (US)
Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…
Report
Malignant Melanoma – Current Treatment – Current Treatment: Physician Insights – Malignant Melanoma (US)
Disease stage, primary tumor resectability, and BRAF mutation status are some of the key parameters influencing the treatment of malignant melanoma. For patients with BRAF mutations, BRAF/MEK…
